SCHEMBL7684539

SCHEMBL7684539

COc1ccccc1NC(=O)c1cn(-c2ccc(F)cc2)c2ncccc2c1=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 7/20 0.59
KCNH2 Q12809 6/20 0.59
IRAK4 Q9NWZ3 1/20 0.50
RXFP1 Q9HBX9 1/20 0.49
TP53 P04637 1/20 0.48
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
MAPK1 P28482 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
RAB9A P51151 1/20 0.45
MET P08581 1/20 0.45
KIT P10721 1/20 0.45
FLT3 P36888 1/20 0.45
PIM1 P11309 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7172242 0.88 PDE4A (0.59) PDE4AKCNH2TP53MAPTMET
SCHEMBL7167976 0.88 PDE4A (0.59) PDE4AKCNH2TP53MEN1KMT2A
SCHEMBL7602515 0.87 PDE4A (0.60) PDE4AKCNH2KDM4ELMNAMET
SCHEMBL7169239 0.87 PDE4A (0.57) PDE4AKCNH2KDM4EL3MBTL1RAB9A
SCHEMBL7172238 0.86 PDE4A (0.56) PDE4AKCNH2TP53KDM4EL3MBTL1
SCHEMBL7974189 0.85 KDM4E (0.58) PDE4AKCNH2TP53KDM4EALDH1A1
SCHEMBL7169646 0.85 PDE4A (0.62) PDE4AKCNH2TDP1RAB9A
SCHEMBL7175717 0.85 PDE4A (0.62) PDE4AKCNH2TP53KDM4ELMNA
SCHEMBL7169134 0.84 PDE4A (0.60) PDE4AKCNH2TP53ALDH1A1MAPT
SCHEMBL7171697 0.84 PDE4A (0.56) PDE4AKCNH2TP53MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020006935-A1 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor DAIICHI ASUBIO PHARMA CO., LTD. (JP) 2002-01-17 US disclosed
US-6297248-B1 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor SUNTORY LIMITED (JP) 2001-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006935-A1 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor PDE3A, PDE5A, PDE3B PDE4A 4/4885KCNH2 559/4885IRAK4 2286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.